<head>
    <link rel="stylesheet" href="css/belief.css">
</head>
<!-- Main -->
<main>
    <div class="tabs">
        <a href="inclusion-criteria.html" class="tab tab--active">TRIAL DESIGN</a>
        <a href="baseline-characteristics.html" class="tab">BASELINE CHARACTERISTICS</a>
    </div>
    <h2 class="primary">BELEODAQ Is for Adult Patients With PTCL at First or Subsequent Relapse<sup>1</sup></h2>
    <h3 class="secondary-variant">The BELIEF trial evaluated the overall response rate (ORR*) with BELEODAQ, a single-agent treatment regimen<sup>1,2</sup>
    </h3>
    <ul>
        <li>
            <h4 class="light">BELIEF was a single-arm, open-label, nonrandomized, international phase 2 study of 129 adult patients with relapsed or refractory (R/R) PTCL<sup>1,2</sup></h4>
        </li>
        <li>
            <h4 class="light">
                120 of the 129 had histologically confirmed PTCL and were evaluable for efficacy<sup>1</sup>
            </h4>
        </li>
        <li>
            <h4 class="light">
                The median time from PTCL diagnosis was 12.0 months (range, 2.6-266.4)<sup>2</sup>
            </h4>
        </li>
    </ul>
    <div class="tabs">
        <a href="inclusion-criteria.html" class="tab">INCLUSION CRITERIA</a>
        <a href="exclusion-criteria.html" class="tab">EXCLUSION CRITERIA</a>
        <a href="dosing-of-beleodaq.html" class="tab">DOSING OF BELEODAQ</a>
        <a href="primary-endpoints.html" class="tab">PRIMARY ENDPOINTS</a>
        <a href="secondary-endpoints.html" class="tab tab--active-variant">SECONDARY ENDPOINTS</a>
        <a href="study-assessment.html" class="tab">STUDY ASSESSMENT</a>
    </div>
    <div class="tab-content">
        <h4 class="light"><strong>Duration of response</strong> per IRC based on both statistical analyses plan (SAP) and IWG beginning when response criteria were first met (CR and PR)<sup>1,2</sup>
        </h4>
        <ul>
            <li>
                <h4 class="light">The end date chosen for the SAP was the date of either progressive disease (PD) or death</h4>
            </li>
            <li>
                <h4 class="light">The end date per IWG criteria was the first subsequent date that relapse or progression was documented with patients who died censored at their last tumor assessment</h4>
            </li>
        </ul>
        <h4 class="semibold">Time to response<sup>2</sup></h4>
    </div>
    <p class="dark"><sup>*</sup>In the BELIEF trial, ORR included patients with a complete response and with a partial response.<sup>1,2</sup></p>
    <p class="light dark">AE, adverse event; ANC, absolute neutrophil count; BMB, bone marrow biopsies; CR, complete response; ECOG, Eastern Cooperative Oncology Group; HSCT, hematopoietic stem cell transplantation; IRC, independent review committee; IWG, International Working Group; PTCL, peripheral T-cell lymphoma; ORR, overall response rate; PD, progressive disease; PR, partial response; R/R relapsed/refractory; SAP, statistical analysis plan.</p>
    <div class="button-group">
        <a href="about.html" class="button justify-left secondary"><i class="fas fa-chevron-left"></i> About BELEODAQ</a>
        <a href="efficacy.html" class="button justify-right">Efficacy <i class="fas fa-chevron-right"></i></a>
    </div>
</main>